| Full text | |
| Author(s): |
Yang, Ji H.
[1, 2]
;
Maciel, Rui M. B.
[1, 2]
;
Nakabashi, Claudia C. D.
[1, 2]
;
Janovsky, Carolina C. P. S.
[1, 2]
;
Padovani, Rosalia P.
[1, 2]
;
Macellaro, Danielle
[1, 2]
;
Camacho, Cleber P.
[1, 2]
;
Osawa, Akemi
[3]
;
Wagner, Jairo
[3]
;
Biscolla, Rosa Paula M.
[1, 2]
Total Authors: 10
|
| Affiliation: | [1] Univ Fed Sao Paulo EPM Unifesp, Escola Paulista Med, Ctr Doencas Tireoide, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo EPM Unifesp, Escola Paulista Med, Lab Endocrinol Mol & Translac, Dept Med, Div Endocrinol, Sao Paulo, SP - Brazil
[3] HIAE, Dept Imagem, Sao Paulo, SP - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | ARCHIVES OF ENDOCRINOLOGY METABOLISM; v. 61, n. 5, p. 416-425, SEP-OCT 2017. |
| Web of Science Citations: | 1 |
| Abstract | |
Objective: To evaluate the clinical utility of F-18-FDG PET/CT in patients with high-risk DTC. Subjects and methods: Single-center retrospective study with 74 patients with high-risk differentiated thyroid cancer (DTC), classified in 4 groups. Group 1: patients with positive sTg or TgAb, subdivided in Group 1A: negative RxWBS and no foci of metastases identified at conventional image (n = 9); Group 1B: RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level (n = 13); Group 2: patients with histological findings of aggressive DTC variants (n = 21) and Group 3: patients with positive RxWBS (n = 31). Results: F-18-FDG PET/CT identified undifferentiated lesions and helped restage the disease in groups 1B and 2. The scan helped guide clinical judgment in 9/13 (69%) patients of group 1B, 10/21 (48%) patients of group 2 and 2/31 (6%) patients of group 3. There was no clinical benefit associated with group 1A. F-18-FDG PET/CT was associated with progressive disease. Conclusion: F-18-FDG PET/CT is a useful tool in the follow-up of patients with high-risk DTC, mainly in the group of RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level and in those with aggressive DTC variants. Additionally, this study showed that F-18-FDG PET/CT was associated with progression and helped display undifferentiated lesions guiding clinical assessments regarding surgeries or expectant treatments. (AU) | |
| FAPESP's process: | 06/60402-1 - Medular carcinoma of the thyroid: revisiting the clinical, molecular biological, biochemical and biological aspects following findings of molecular genetics |
| Grantee: | Rui Monteiro de Barros Maciel |
| Support Opportunities: | Research Projects - Thematic Grants |